港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

487.748

+5.3911.12%

漲家數：20

跌家數：7

平家數：6

市盈率：- -

高：489.841

開：482.072

低：481.405

收：482.357

成交量：1,783.66萬

成交額：4.47億

市值：3,101.37億

流通市值：2,755.27億

資料載入中...

總覽新聞資訊

勁方醫藥-B(02595)9月9日斥資196.08萬港元回購7.5萬股

康寧傑瑞製藥-B(09966)9月9日斥資98.97萬港元回購11.8萬股

和鉑醫藥-B(02142)：合作伙伴Solstice Oncology完成2.25億美元A輪融資並正式啓動運營

和鉑醫藥合作方Solstice Oncology完成2.25億美元A輪融資，推進新輔助腫瘤免疫療法Porustobart

和鉑醫藥宣佈其合作伙伴Solstice Oncology完成2.25億美元A輪融資，加速推進新輔助腫瘤免疫療法普魯蘇拜單抗

歸創通橋(02190.HK)9月9日耗資約112.29萬港元回購5.35萬股

賽諾醫療：關於參加上海證券交易所科創板2026年半年度醫療器械及醫療設備行業集體業績説明會的公告

迪哲醫藥(688192.SH)：比瑞替尼治療瀰漫性大B細胞淋巴瘤研究成果獲《血液腫瘤期刊》發表

《大行》瑞銀：中國製藥股上半年業績好壞參半首選先聲藥業(02096.HK)

阿斯达克财经

《大行》里昂：中國創新藥板塊重返Alpha主導宏觀波動或提供買入機會

阿斯达克财经

港股異動 | 維亞生物(01873)升逾5% 朗華製藥CDMO兩個新商業化項目放量為業績作出重要貢獻

中銀國際：醫藥中報業績逐步修復行業進入反轉周期

港股異動 | 和鉑醫藥-B(02142)早盤升逾4% 超長效TSLP抗體哮喘II期成功三期臨床已啓動

2026國談第五日：商保創新藥目錄價格協商開始多家藥企攜核藥、CAR-T新藥等重磅藥物進場

我武生物董事長因個人原因辭職；諾華新藥III期臨床未達主要終點 | 醫藥早參

每日经济新闻

中藥創新從「經驗方」走到「數據方」

港股震盪走弱：資源醫藥「扛大旗」，科技股「摔跟頭」

諾華製藥(NVS)股票9月8日開盤下跌12.63%：釋放什麼信號？

TradingKey中文

同源康醫藥-B(02410)董事長、執行董事兼總裁吳豫生擬增持公司股份

和鉑醫藥-B(02142)：HBM9378/WIN378治療哮喘的 II期臨床取得陽性的中期結果及III期研究啓動

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK1574/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":487.74753,"timestamp":1789611159244,"preClose":482.35672,"halted":0,"volume":17836607,"delay":0,"changeRate":0.011176,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":5.390808,"latestTime":"09-17 10:12:40","open":482.07187,"high":489.841,"low":481.40475,"amount":446798544,"amplitude":0.01749,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"午間休市","tradingStatus":4,"beginTime":1789617600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"pbRate":3.604829,"peRate":160.310337,"turnoverRate":0.000679,"increases":20,"decrements":7,"flats":5,"marketCap":310137082512,"floatMarketCap":275527112584},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":489.841,"amplitude":0.01749,"preClose":482.35672,"low":481.40475,"pbRate":"3.604829","latestPrice":487.74753,"volume":17836607,"delay":0,"open":482.07187,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":496.758,"twentyDayClose":517.015,"sixtyDayClose":440.071,"secType":"PLATE","market":"HK","turnoverRate":0.000679,"peRate":160.310337,"marketCap":310137082512,"floatMarketCap":275527112584,"timestamp":1789611159244,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":20,"down":7,"flat":6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666538468","title":"勁方醫藥-B(02595)9月9日斥資196.08萬港元回購7.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538468","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538468?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:11","pubTimestamp":1788955898,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月9日，该公司斥资196.08万港元回购7.5万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1515","02595","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666690538","title":"康寧傑瑞製藥-B(09966)9月9日斥資98.97萬港元回購11.8萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666690538","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666690538?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:57","pubTimestamp":1788955030,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年9月9日斥资98.97万港元回购11.8万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260909/32365182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587444","title":"和鉑醫藥-B(02142)：合作伙伴Solstice Oncology完成2.25億美元A輪融資並正式啓動運營","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587444","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587444?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:13","pubTimestamp":1788952398,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布公告，公司的合作伙伴公司Solstice Oncology 已完成2.25亿美元的A轮融资并正式启动运营。Solstice是一家临床阶段的肿瘤免疫公司，致力于在新辅助治疗阶段更早地干预癌症。MSS型是结肠癌中占比最大的亚型，迄今为止该患者群体仍未能从免疫治疗中获益。该2期临床试验预计将于 2026年第四季度初启动患者入组，并预期将于2027年下半年取得该研究数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)：合作伙伴Solstice Oncology完成2.25亿美元A轮融资并正式启动运营","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136108597","title":"和鉑醫藥合作方Solstice Oncology完成2.25億美元A輪融資，推進新輔助腫瘤免疫療法Porustobart","url":"https://stock-news.laohu8.com/highlight/detail?id=1136108597","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136108597?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:13","pubTimestamp":1788952393,"startTime":"0","endTime":"0","summary":"和铂医药的合作伙伴Solstice Oncology宣布，已成功完成2.25亿美元的A轮融资。这笔资金将用于加速其核心候选药物Porustobart的临床开发，该药物定位为新辅助免疫肿瘤学疗法。Solstice Oncology表示，所筹资金将重点投向Porustobart的后续临床试验，旨在探索该药物在早期肿瘤治疗中的应用潜力，以期在手术前缩小肿瘤、改善患者预后。Porustobart作为一种创新免疫疗法，其设计初衷是在标准手术干预前调动患者自身免疫系统对抗肿瘤。Solstice Oncology的此番布局，有望为这一赛道注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1574","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539369","title":"和鉑醫藥宣佈其合作伙伴Solstice Oncology完成2.25億美元A輪融資，加速推進新輔助腫瘤免疫療法普魯蘇拜單抗","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539369","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539369?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:12","pubTimestamp":1788952320,"startTime":"0","endTime":"0","summary":"普鲁苏拜单抗治疗结肠癌的2期试验将于2026年第四季度初启动患者入组。和铂医药创始人、董事长兼首席执行官王劲松博士表示：\"我们非常高兴看到Solstice Oncology在顶级投资者的有力支持下成功启动运营，并将普鲁苏拜单抗推进至新辅助治疗领域。关于Solstice Oncology Solstice Oncology是一家临床阶段的肿瘤免疫公司，专注于新辅助治疗领域。Solstice成立于2026年2月，核心团队在肿瘤领域拥有数十年成功研发和推进免疫治疗药物的丰富经验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5043403_ZH43403_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5043403_ZH43403_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","02142","BK1583","BK1574","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666821805","title":"歸創通橋(02190.HK)9月9日耗資約112.29萬港元回購5.35萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666821805","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666821805?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:45","pubTimestamp":1788950746,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1100","BK1574","BK1587","02190"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666582190","title":"賽諾醫療：關於參加上海證券交易所科創板2026年半年度醫療器械及醫療設備行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2666582190","media":"同花顺","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666582190?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:39","pubTimestamp":1788950340,"startTime":"0","endTime":"0","summary":"    证券日报网讯9月9日，赛诺医疗发布公告称，公司计划于2026年9月17日15：00-17：00参加上海证券交易所组织的科创板2026年半年度医疗器械及医疗设备行业集体业绩说明 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679749361.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679749361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["09996","BK1583","BK4585","MEDX","BK1100","IHI","LNGR","KSTR","AGNG","HART","RSPH","688108","PTH","BK4588","XHE","IEIH","BK1574","LGHT","MDEV","GDOC","159883","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666583145","title":"迪哲醫藥(688192.SH)：比瑞替尼治療瀰漫性大B細胞淋巴瘤研究成果獲《血液腫瘤期刊》發表","url":"https://stock-news.laohu8.com/highlight/detail?id=2666583145","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666583145?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 15:56","pubTimestamp":1788940569,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药 发布公告，公司自主研发的全球首创、可完全穿透血脑屏障的非共价LYN/BTK双靶点抑制剂比瑞替尼单药治疗复发/难治弥漫性大B细胞淋巴瘤II期临床研究结果正式发表于国际权威血液学期刊《血液肿瘤期刊》。TAI-SHAN9研究入组患者既往接受过1至5线系统性治疗。研究结果显示，在50mg和75mg剂量下，比瑞替尼单药治疗在不同分子亚型中均展现出广谱的抗肿瘤活性，并呈现出可管理的安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","159938","BK0239","688192","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666983588","title":"《大行》瑞銀：中國製藥股上半年業績好壞參半  首選先聲藥業(02096.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666983588","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666983588?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 15:18","pubTimestamp":1788938280,"startTime":"0","endTime":"0","summary":"瑞银发表研报报告指，中国制药股上半年业绩好坏参半，在九家评级的制药公司中，有五家业绩好过市场预期，分别为翰森制药、先声药业、中生制药、石药集团及科伦药业，联邦制药表现大致符合预期，而恒瑞医药、三生制药及华东医药表现则逊预期，全数给予“买入”评级。瑞银列先声药业行业首选股，指出先声药业是唯一上调2026年指引的公司，经调整纯利增长目标由30%上调至45%，收入增长维持30%，给予目标价16.6元。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210308110543834_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210308110543834_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543624/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543624/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","BK1574","01477","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666304134","title":"《大行》里昂：中國創新藥板塊重返Alpha主導  宏觀波動或提供買入機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2666304134","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666304134?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 12:08","pubTimestamp":1788926880,"startTime":"0","endTime":"0","summary":"里昂发表报告指，中国创新药板块正重回以公司基本面与个股超额收益为主导的市场，公司特定基本面相对宏观因素的影响力回升。该行预期，随市场对创新药企临床及BD执行信心改善，基本面角色将愈趋重要；短期宏观波动或提供趁低买入、验证此观点的机会。该行认为，重大临床读出与BD活动加速，正面催化剂窗口正在打开。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543577/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543577/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1720050803.USD","LU1255011170.USD","LU2097828805.USD","IE00BYV24P56.USD","BK1593","IE00BZ08YS42.EUR","IE00B031HY20.USD","603259","LU0327786744.USD","LU0502904849.HKD","LU2399975544.HKD","LU1152091754.HKD","LU1188198961.HKD","LU0140636845.USD","LU0540923850.HKD","LU0708995583.HKD","LU0417516571.SGD","01099","LU1820825898.SGD","LU2097828631.EUR","603233","LU0463099449.HKD","LU1046422090.SGD","LU1655091616.SGD","SG9999015978.USD","BK0226","LU0417516738.SGD","LU1961090484.USD","IE00BVYPNQ40.USD","LU1831875114.USD","SHTDY","LU0326950275.SGD","BK0028","LU0405327148.USD","LU1328615791.USD","LU0348827113.USD","LU1152091168.USD","BK0239","LU1064131003.USD","LU0320764599.SGD","LU0572944931.SGD","LU1951186391.HKD","03692","HK0000165453.HKD","LU1226288170.HKD","LU1997245177.USD","LU2148510915.USD","BK1589","BK1141","BK1574","BK1587","SG9999015945.SGD","LU1115378108.SGD","LU2580892789.USD","LU2580892862.HKD","LU1226288253.USD","LU1813983027.USD","02162","LU0880133367.SGD","IE00BVYPNP33.GBP","LU2476274720.SGD","LU2097828714.EUR","LU1226287529.USD","BK0196","LU0348735423.USD","LU0455707207.USD","BK0188","IE00BMCWC346.EUR","LU1794554557.SGD","BK0114","SG9999015952.SGD","09926","00867","LU0607220059.USD","LU1781817850.SGD","02595","IE00BZ08YR35.GBP","LU1146622755.USD","BK0012","SG9999004220.SGD","BK1161","LU0348766576.USD","BK1521","LU0244354667.USD","LU1969619763.USD","LU1993786604.SGD","LU0348784397.USD","LU1960683339.HKD","SBHMY","LU0315179316.USD","LU2125910500.SGD","LU0348783233.USD","KURE","LU2476274308.USD","LU0640798160.USD","BK1191","IE00B5MMRT66.SGD","LU1997244956.HKD","LU0348825331.USD","BK1500","BK1583","LU1328277881.USD","LU0501845795.SGD","LU1008478684.HKD","LU2495084118.USD","01177","LU1807302812.USD","LU0072913022.USD","LU2097828557.USD","300765","BK1197","IE00BPRC5H50.USD","IE00BGHQDM52.EUR","LU2778985437.USD","LU2045819591.USD","BK0209","IE0008369823.USD","LU2328871848.SGD","LU2242644610.SGD","BK1515","01801","LU0348767384.USD","LU0149534421.HKD","LU1226287792.SGD","LU0314109678.HKD","600276","BK0060","SG9999015986.USD","LU0052750758.USD","LU2039709279.SGD","LU0417516902.SGD","BK1576","IE00BZ08YT58.USD","IE00B543WZ88.USD","IE0008368742.USD","LU0067412154.USD","LU2289578879.USD","LU2488822045.USD","BK0185","01093","LU0405327494.USD","LU1997245094.SGD","LU0469268626.HKD","BK0183","LU1064130708.USD","02359","LU2097828474.EUR","01276","LU1580142542.USD","LU0634319403.HKD","SG9999004311.SGD","LU1226287875.USD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666830114","title":"港股異動 | 維亞生物(01873)升逾5% 朗華製藥CDMO兩個新商業化項目放量為業績作出重要貢獻","url":"https://stock-news.laohu8.com/highlight/detail?id=2666830114","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666830114?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 11:25","pubTimestamp":1788924355,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维亚生物(01873)涨超5%，截至发稿，涨5.17%，报1.425港元，成交额754.05万港元。消息面上，维亚生物近期披露上半年业绩，招商证券指出，26H1公司收入同比+21.0%，主要得益于朗华制药CDMO两个新商业化项目放量的重要贡献。具体看，26H1朗华制药收入6.01亿元、同比+47.0%(固定汇率+52.2%)。两个重磅新商业化项目稳步推进，多肽项目已商业化上市、进入备货放量阶段；小分子项目处于PPQ生产阶段、预计2027年商业化上市，二者将成为未来几年CDMO持续增长的核心动力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","CDMO","BK1191","VXUS","BK1576","BK4585","BK4588","BK4139","BK1141","BK1574","01873","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666114301","title":"中銀國際：醫藥中報業績逐步修復 行業進入反轉周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2666114301","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666114301?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:54","pubTimestamp":1788922458,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中银国际发布研报称，医药板块上市公司26年中报已经披露完毕，整体看，医药行业整体增长韧性十足，结构性修复持续演绎。关注底部边际修复板块，如医疗器械、原料药以及药店等医疗器械细分板块来看，医疗设备呈弱复苏态势，高值耗材增长稳健，IVD板块触底回升，低值耗材板块盈利明显修复。IVD板块，低基数效应与海外业务持续放量驱动行业盈利显著修复。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","159938","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666097963","title":"港股異動 | 和鉑醫藥-B(02142)早盤升逾4% 超長效TSLP抗體哮喘II期成功 三期臨床已啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2666097963","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666097963?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:38","pubTimestamp":1788921514,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B早盘涨超4%。截至发稿，涨4.67%，报15.23港元，成交额5980.62万港元。消息面上，9月8日，和铂医药及科伦博泰宣布，其合作伙伴Windward Bio已公布POLARIS-1临床研究II期部分的阳性中期结果。该研究正在评估超长效TSLP双抗HBM9378/WIN378每年两次给药方案治疗哮喘的效果。此外，Windward Bio计划于 2027 年上半年启动第二项三期临床研究POLARIS-2。公司董事会表示，此次获纳入港股通，将为公司引入更广泛的投资者基础，进一步提升股份流动性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","KCAI","BK1583","02142","BK4585","BK1161","VXUS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666305240","title":"2026國談第五日：商保創新藥目錄價格協商開始 多家藥企攜核藥、CAR-T新藥等重磅藥物進場","url":"https://stock-news.laohu8.com/highlight/detail?id=2666305240","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666305240?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 09:06","pubTimestamp":1788915970,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159992","06978","BK1161","MEDX","BK1574","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666308479","title":"我武生物董事長因個人原因辭職；諾華新藥III期臨床未達主要終點 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2666308479","media":"每日经济新闻","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666308479?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 07:01","pubTimestamp":1788908468,"startTime":"0","endTime":"0","summary":"丨2026年9月9日星期三丨NO.1诺华制药DM1药物III期临床未达主要终点9月8日，诺华制药宣布，其评估del-desiran治疗1型强直性肌营养不良（DM1）的III期HARBOR研究未达到主要终点。公司表示，将进一步分析完整数据，并与监管机构沟通后确定后续开发路径。点评：消息放出后，诺华股价明显受挫，反映资本市场对该管线预期大幅下调。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093868484469.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093868484469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","IE00BFTCPJ56.SGD","BK0028","LU0211331839.USD","BK1515","300357","PPH","MEDX","BK4585","BK4578","BK4588","LU0070302665.USD","NVS","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4532","IE0002141913.USD","BK4007","LU0320765489.SGD","LU0208291251.USD","159938","IE00B2B36J28.USD","BK1161","IE00BJT1NW94.SGD","BK0239","BK1574","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666654371","title":"中藥創新從「經驗方」走到「數據方」","url":"https://stock-news.laohu8.com/highlight/detail?id=2666654371","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666654371?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 23:28","pubTimestamp":1788881280,"startTime":"0","endTime":"0","summary":"传统中药源于历代医家的经验积累，但面对现代医学的检验标准，如何用可重复、可量化的数据证明其安全性和有效性，始终是中药现代化进程中绕不开的一道题。近期，《证券日报》记者在梳理相关上市公司公告时注意到，有一个词被越来越多的中药企业频繁提及——循证医学。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868422064.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868422064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","MEDX","BK1574","BK4159","06978","LNGR","RCT","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665620376","title":"港股震盪走弱：資源醫藥「扛大旗」，科技股「摔跟頭」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665620376","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665620376?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 22:13","pubTimestamp":1788876780,"startTime":"0","endTime":"0","summary":"今日(9月8日)，港股市场整体震荡走弱，各大核心指数涨跌分化明显。截至收盘，恒生指数微跌0.38%，报25317.18点，单日下跌95.94点；国企指数同步小幅下行，跌幅0.38%，收报8397.32点；恒生科 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260908/c679714830.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260908/c679714830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["07568","BK4585","09834","09086","159938","03455","09939","VGT","BK1161","XLK","VXUS","BK4588","TTTN","07261","KCAI","07266","BK1147","02834","03086","BK1574","BK1515","07522","03034"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376381","title":"諾華製藥(NVS)股票9月8日開盤下跌12.63%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376381","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665376381?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:48","pubTimestamp":1788875309,"startTime":"0","endTime":"0","summary":"• 在 del-desiran 的 III 期 HARBOR 临床试验宣告失败后，诺华股价下跌。\n• pelacarsen 的心血管试验同样未能达到减少心血管事件的主要终点。\n• 多项研发管线遭遇挫折，加剧了投资者的审视，并推升了结构性增长风险。","market":"us","thumbnail":"https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156193-market-movers-nvs-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","NVS","LU0211331839.USD","BK4007","BK4578","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4588","IE0009355771.USD","BK4585","BK1191","IE00B4R5TH58.HKD","LU0320765489.SGD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0070302665.USD","LU0208291251.USD","IE0002141913.USD","MEDX","BK4532","PPH","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665758793","title":"同源康醫藥-B(02410)董事長、執行董事兼總裁吳豫生擬增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2665758793","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665758793?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:23","pubTimestamp":1788873797,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)发布公告，本公司董事长、执行董事兼总裁吴豫生博士(吴博士)已告知本公司，吴博士近日于公开市场购买本公司股份，未来可能继续根据市场情况购买本公司股份，目前预计增持总金额不超过200万港元。吴博士已向本公司承诺，他在未来一个月内通过增持获得的本公司股份将分别自购入日起自愿锁定六个月，并在锁定期内不会出售或通过其他方式转让有关股份。吴博士表示，本次股份增持的资金来自其自有资金。此次增持股份彰显其对本集团未来发展前景的坚定信念及充分信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","02410","BK1515","BK1161","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665738153","title":"和鉑醫藥-B(02142)：HBM9378/WIN378治療哮喘的 II期臨床取得陽性的中期結果及III期研究啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2665738153","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665738153?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:54","pubTimestamp":1788872083,"startTime":"0","endTime":"0","summary":"HBM9378/WIN378是目前已知唯一一款通过双位点结合TSLP来阻断其信号通路的在研药物，能够干扰TSLP与其两个共受体在上皮细胞表面的结合。该研究亦同时评估HBM9378/WIN378对肺功能和气道炎症生物标志物的影响。其III期部分正在评估两种每年两次给药剂量的HBM9378/WIN378对比安慰剂的疗效，主要终点为重度哮喘患者的年化哮喘急性发作率。HBM9378/WIN378耐受性及安全性良好，截至数据截止日期，未观察到治疗相关严重不良事件、退出或停药。注射部位反应发生率低于1%，抗药物抗体发生率为2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)：HBM9378/WIN378治疗哮喘的 II期临床取得阳性的中期结果及III期研究启动","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1583","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":10,"totalSize":326,"code":"91000000","status":"200"}]}}